Researchers at Washington University report: DiviTum® can evaluate the biologic activity of blockbuster breast cancer drug after two weeks
Uppsala, Sweden, November 23, 2017. Results of a study from Washington University, St Louis, demonstrate that the DiviTum® can evaluate the biologic activity of Pfizer’s breast cancer drug palbociclib (Ibrance®) in just two weeks are published in the latest edition of the scientific journal Breast Cancer Research and Treatment. This shortening of the response evaluation window can improve outcome and increase quality of life for breast cancer patients.Led by Dr Cynthia Ma, the study investigated 50 women with breast cancer treated with standard endocrine therapy in combination with Ibrance®